Skoner DP, Gentile DA, Doyle WJ
Effect on growth of long-term treatment with intranasal triamcinolone acetonide aqueous in children with allergic rhinitis. [Journal Article, Research Support, Non-U.S. Gov't]
Ann Allergy Asthma Immunol 2008 Oct; 101(4):431-6.
BACKGROUND: Guidelines recommend treatment with intranasal corticosteroids for patients with allergic rhinitis (AR), but concerns remain about possible adverse effects.
OBJECTIVE: To present the 1- and 2-year growth results for children with AR treated with triamcinolone acetonide aqueous nasal spray.
METHODS: Thirty-nine children (aged 6.1-14.3 years at study entry) were treated with triamcinolone acetonide aqueous for 1 year, and a subset of 30 children completed a second year of treatment. The dose was physician titered to achieve control over AR symptoms. For each child, statural heights at baseline and at the 1- and 2-year (where available) visits, together with growth rates, were measured and were compared with predicted values.
RESULTS: There were no significant differences between measured and predicted heights at the 1- and 2-year visits. The mean (SD) measured--predicted difference was 0.3 (2.2) cm (95% confidence interval, -0.4 to 1.0 cm) at the 1-year visit and 0.5 (3.0) cm (95% confidence interval, -0.6 to 1.6 cm) at the 2-year visit. Mean differences in measured and predicted growth rates were nonsignificant at the 1- and 2-year visits.
CONCLUSIONS: Triamcinolone acetonide aqueous titered to control AR symptoms and given for 1 or 2 years had no significant effect on statural growth in children with AR.
More from this journalRelated subjects (MeSH) |
